BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22503317)

  • 1. Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms.
    Hamilton NA; Liu TC; Cavatiao A; Mawad K; Chen L; Strasberg SS; Linehan DC; Cao D; Hawkins WG
    Surgery; 2012 Jul; 152(1):107-13. PubMed ID: 22503317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASO Author Reflections: Pancreatic Neuroendocrine Tumor Recurrence and Survival Predicted by Ki67.
    Nieveen van Dijkum EJM
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):531-532. PubMed ID: 30519760
    [No Abstract]   [Full Text] [Related]  

  • 4. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
    Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
    Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes.
    Cheng Y; Zhan H; Wang L; Xu J; Zhang G; Zhang Z; Hu S
    Front Med; 2016 Dec; 10(4):444-450. PubMed ID: 27757796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnostic value of FNA biopsy in grading pancreatic neuroendocrine tumors.
    Laskiewicz L; Jamshed S; Gong Y; Ainechi S; LaFemina J; Wang X
    Cancer Cytopathol; 2018 Mar; 126(3):170-178. PubMed ID: 29266776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
    Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
    Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection.
    Milione M; Maisonneuve P; Pellegrinelli A; Spaggiari P; Centonze G; Coppa J; Delconte G; Droz Dit Busset M; Lanhazo O; Pruneri G; Mazzaferro V
    Eur J Surg Oncol; 2019 May; 45(5):755-760. PubMed ID: 30366875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape.
    Haugvik SP; Kaemmerer D; Gaujoux S; Labori KJ; Verbeke CS; Gladhaug IP
    Curr Oncol Rep; 2016 May; 18(5):28. PubMed ID: 26984415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics, Treatment, Outcomes, and Survival in Neuroendocrine G1 and G2 Pancreatic Tumors: Experiences From a Single Tertiary Referral Center.
    Calissendorff J; Bjellerup-Calissendorff F; Bränström R; Juhlin CC; Falhammar H
    Front Endocrinol (Lausanne); 2021; 12():657698. PubMed ID: 33927695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): A systematic review.
    Pezzilli R; Partelli S; Cannizzaro R; Pagano N; Crippa S; Pagnanelli M; Falconi M
    Adv Med Sci; 2016 Mar; 61(1):147-53. PubMed ID: 26774266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study.
    Larghi A; Capurso G; Carnuccio A; Ricci R; Alfieri S; Galasso D; Lugli F; Bianchi A; Panzuto F; De Marinis L; Falconi M; Delle Fave G; Doglietto GB; Costamagna G; Rindi G
    Gastrointest Endosc; 2012 Sep; 76(3):570-7. PubMed ID: 22898415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
    Merola E; Rinke A; Partelli S; Gress TM; Andreasi V; Kollár A; Perren A; Christ E; Panzuto F; Pascher A; Jann H; Arsenic R; Cremer B; Kaemmerer D; Kump P; Lipp RW; Agaimy A; Wiedenmann B; Falconi M; Pavel ME
    Ann Surg Oncol; 2020 May; 27(5):1348-1355. PubMed ID: 31720931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High vimentin expression with E-cadherin expression loss predicts a poor prognosis after resection of grade 1 and 2 pancreatic neuroendocrine tumors.
    Zhou B; Xiang J; Jin M; Zheng X; Li G; Yan S
    BMC Cancer; 2021 Mar; 21(1):334. PubMed ID: 33789624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic neuroendocrine neoplasm: correlation between computed tomography enhancement patterns and prognostic factors of surgical and endoscopic ultrasound-guided fine-needle aspiration biopsy specimens.
    Tatsumoto S; Kodama Y; Sakurai Y; Shinohara T; Katanuma A; Maguchi H
    Abdom Imaging; 2013 Apr; 38(2):358-66. PubMed ID: 22945422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors.
    Wei IH; Harmon CM; Arcerito M; Cheng DF; Minter RM; Simeone DM
    Ann Surg; 2014 Dec; 260(6):1088-94. PubMed ID: 25389924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
    Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
    Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fine-needle aspiration biopsy of pancreatic neuroendocrine tumors: Correlation between Ki-67 index in cytological samples and clinical behavior.
    Díaz Del Arco C; Esteban López-Jamar JM; Ortega Medina L; Díaz Pérez JÁ; Fernández Aceñero MJ
    Diagn Cytopathol; 2017 Jan; 45(1):29-35. PubMed ID: 27863178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
    Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
    Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.